TTrialPathMatch Me to Trials
← Back to trials
RecruitingPancreas Cancer With Hepatic MetastasePancreas AdenocarcinomaDuodenal Cancer

Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma

Eligible age

18–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this observational study is to evaluate whether hepatic artery infusion pump (HAIP) chemotherapy can improve outcomes in patients with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant metastases after surgery and systemic chemotherapy. The main questions it aims to answer are: Does HAIP chemotherapy improve liver tumor response based on imaging criteria (RECIST)? What are the progression-free survival and overall survival outcomes in this patient population? Participants will: Undergo placement of a hepatic artery infusion pump as part of standard clinical care Receive floxuridine (FUDR)-based chemotherapy through the pump Have clinical data, imaging results, and laboratory markers (e.g., ctDNA, CEA, CA 19-9) collected from their medical records over time

Sponsor: AdventHealth

You may qualify if…

  • ✓ Age 18-80 years
  • ✓ Histologically confirmed pancreatic or duodenal adenocarcinoma
  • ✓ Completed or currently receiving curative-intent treatment
  • ✓ Evidence of isolated or liver-dominant metastases (radiographic or clinical)
  • ✓ Deemed clinically eligible for hepatic artery infusion pump (HAIP) placement and floxuridine (FUDR)-based chemotherapy by a multidisciplinary oncology team
  • ✓ Scheduled for HAIP placement at AdventHealth Orlando

You may not qualify if…

  • ✕ \- Patients who are clinically ineligible for HAIP placement or FUDR therapy are excluded

Where it's recruiting

Florida

Orlando

Source: ClinicalTrials.gov · NCT07845617 · last updated 2026-09-29

Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Re · TrialPath